Home Blog of Signal Transduction Cell Cycle CDK Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive Her2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive Her2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

INTRODUCTION:

The synthesis of CDK4/6 inhibitors with treatment of endocrine in start two series of treatment has been widely accepted as the standard for Esterogen (ER)-positive MBC (metastatic breast cancer) patients. In spite of, the activity of CDK4/6 inhibitors in MBC patients who had progressed despite receiving multiple lines of treatment is not well understood.

AIM:

We aimed to report on the activity and safety of a CDK4/6 inhibitor (palbociclib) for patients who had failed at least three lines of treatment for ER+/ MBC.

STUDY DESIGN:

Multi-center retrospective observational cohort study.

METHODS:

In this retrospective observational cohort study, we included 43 patients, whom were given palbociclib after at least 3 lines of systemic treatment for ER-positive/HER2-negative MBC.

RESULTS:

Overall, the median progression-free survival in our population was 7 months (25th percentile = 4, 75th percentile = 10) (Figure 1) and median overall survival was 11 months (25th percentile = 6, 75th percentile = 19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only 6 (14%) patients.

CONCLUSION:

We demonstrated that the efficacy of palbociclib among heavily treated hormone receptor-positive/HER2-negative advanced BC patients was acceptable clinical benefit, and it was generally well tolerated among this population.

Related Products

Cat.No. Product Name Information
S1579 Palbociclib Isethionate Palbociclib Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Related Targets

CDK